EGFR upregulation drives signaling reactivation during EGFR inhibition in glioblastoma without broad kinome rewiring

Abstract

BackgroundEpidermal growth factor receptor (EGFR) amplification occurs in [~]50% of IDH-wildtype glioblastoma (GBM) cases, frequently accompanied by expression of the oncogenic EGFRvIII variant. Although EGFR represents an attractive therapeutic target, EGFR-directed therapies have shown limited clinical efficacy in GBM. Resistance to kinase inhibitors is frequently attributed to activation of compensatory signaling pathways ("kinome rewiring"). We therefore investigated whether EGFR inhibition in GBM induces broad adaptive kinase responses that could be co-targeted to overcome resistance. MethodsWe molecularly profiled 29 patient-derived GBM cell lines for EGFR status and selected five representative models spanning EGFR amplification states for functional analyses. Cells were treated with EGFR inhibitors and responses were assessed using viability assays, time-resolved immunoblotting, and phosphoproteomics (LC-MS/MS) with kinase activity inference. ResultsEGFR inhibitors preferentially impaired viability in EGFR-driven models and transiently reduced EGFR phosphorylation during the initial response. However, partial restoration of EGFR phosphorylation and downstream signaling occurred after 24 hours of inhibitor exposure. Phosphoproteomics revealed no evidence of broad kinome rewiring within this timeframe but instead identified increased EGFR abundance, associated with partial restoration of EGFR pathway activity. The phosphorylated-to-total EGFR ratio remained stable, indicating that increased EGFR abundance may enable persistent residual kinase activity despite continued, but incomplete, target inhibition. ConclusionsEarly responses to EGFR inhibition in GBM were not characterized by broad kinome rewiring but by restoration of EGFR signaling associated with increased EGFR abundance. These findings suggest that adaptive signaling remains largely EGFR-dependent despite inhibitor exposure, identifying regulation of EGFR abundance as a potential contributor to therapeutic resistance. Key points- Early responses to EGFR inhibition occur without evidence of broad kinome rewiring. - EGFR signaling is restored during sustained inhibitor exposure. - Increased EGFR abundance is associated with restoration of pathway activity. Importance of the studyAdaptive resistance to EGFR-targeted therapies in GBM is commonly attributed to activation of alternative signaling pathways. Using patient-derived GBM models and phosphoproteomic profiling, we show that early adaptive responses to EGFR inhibition are not characterized by broad kinome signaling rewiring but instead remain centered on reactivation of EGFR signaling. Our findings suggest that increased EGFR abundance in response to inhibitor exposure may enhance residual EGFR signaling sufficiently to partially restore downstream pathway activity. These results indicate that early adaptive responses to EGFR inhibition may remain largely EGFR-dependent, potentially limiting the effectiveness of strategies primarily aimed at co-targeting alternative signaling pathways. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=105 SRC="FIGDIR/small/744581v1_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@8d4ea3org.highwire.dtl.DTLVardef@125e3eeorg.highwire.dtl.DTLVardef@9742c0org.highwire.dtl.DTLVardef@9f4fa8_HPS_FORMAT_FIGEXP M_FIG C_FIG